A randomized double‐blind study of low‐molecular‐weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum)

@article{Cosmi2012ARD,
  title={A randomized double‐blind study of low‐molecular‐weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum)},
  author={B. Cosmi and M. Filippini and D. Tonti and G. Avruscio and A. Ghirarduzzi and E. Bucherini and G. Camporese and D. Imberti and G. Palareti},
  journal={Journal of Thrombosis and Haemostasis},
  year={2012},
  volume={10}
}
Summary.  Background:  Optimal doses and duration of low‐molecular‐weight heparin (LMWH) for the treatment of superficial vein thrombosis (SVT) are still uncertain. 
36 Citations
Superficial vein thrombosis: a current approach to management
Controversies in venous thromboembolism: to treat or not to treat superficial vein thrombosis.
The incidence of heparin-induced thrombocytopenia in patients treated with low molecular weight heparin for superficial vein thrombosis.
...
1
2
3
4
...

References

SHOWING 1-10 OF 30 REFERENCES
Heparin and low-molecular-weight heparin.
Fondaparinux for the treatment of superficial-vein thrombosis in the legs.
...
1
2
3
...